{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:55:41Z","timestamp":1790819741943,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T00:00:00Z","timestamp":1389312000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T00:00:00Z","timestamp":1389312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>T cells orchestrate joint inflammation in rheumatoid arthritis (RA), yet they are difficult to study due to the small numbers of antigen-specific cells. The goal of this study was to characterize a new humanized model of autoimmune arthritis and to describe the phenotypic and functional changes that occur in autoimmune T cells following the induction of pathological events.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>We developed a double transgenic mouse containing both the HLA-DR1 transgene and an HLA-DR1-restricted collagen-specific TCR in order to obtain large numbers of antigen-specific T cells that can be used for immunologic studies.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p><jats:italic>In vitro<\/jats:italic>, CII-specific T cells from this mouse proliferated vigorously in response to the CII immunodominant peptide A2 and the cells altered their phenotype to become predominately CD62L<jats:sup>low<\/jats:sup> and CD44<jats:sup>high<\/jats:sup> \u201cactivated\u201d T cells. The response was accompanied by the production of Th1, Th2, and Th17-type cytokines. Following immunization with bovine CII\/CFA, these mice develop an accelerated arthritis compared to single transgenic HLA-DR1 mice. On the other hand, when the mice were treated orally with the analog peptide A12, (a suppressive analog of collagen we have previously described), arthritis was significantly suppressed, despite the fact that &gt;90% of the CD4+ T cells express the TCR Tg. In GALT tissues taken from the A12-treated mice, IL-2, IFN-\u03b3, and IL-17 production to the autoimmune collagen determinant dropped while high levels of IL-10 and IL-4 were produced.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>We have developed a humanized model of autoimmune arthritis that will be useful for the study of T cell directed therapies as well as T cell mediated mechanisms of autoimmune diseases.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/ar4433","type":"journal-article","created":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T13:57:16Z","timestamp":1389362236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Characterization of T cell phenotype and function in a double transgenic (collagen-specific TCR\/HLA-DR1) humanized model of arthritis"],"prefix":"10.1186","volume":"16","author":[{"given":"Bo","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Cullins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward F","family":"Rosloniec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold E","family":"Postlethwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda K","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"4100_CR1","doi-asserted-by":"publisher","first-page":"11433","DOI":"10.1073\/pnas.190335897","volume":"97","author":"AL Meyer","year":"2000","unstructured":"Meyer AL, Trollmo C, Crawford F, Marrack P, Steere AC, Huber BT, Kappler J, Hafler DA: Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers. Proc Natl Acad Sci USA. 2000, 97: 11433-11438. 10.1073\/pnas.190335897.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4100_CR2","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.4049\/jimmunol.1103598","volume":"188","author":"S Oh","year":"2012","unstructured":"Oh S, Aitken M, Simons DM, Basehoar A, Garcia V, Kropf E, Caton AJ: Requirement for diverse TCR specificities determines regulatory T cell activity in a mouse model of autoimmune arthritis. J Immunol. 2012, 188: 4171-4180. 10.4049\/jimmunol.1103598.","journal-title":"J Immunol"},{"key":"4100_CR3","first-page":"11","volume":"15","author":"EF Rosloniec","year":"2010","unstructured":"Rosloniec EF, Cremer M, Kang AH, Myers LK, Brand DD: Collagen-induced arthritis. Curr Protoc Immunol. 2010, 15: 11-25.","journal-title":"Curr Protoc Immunol"},{"key":"4100_CR4","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1084\/jem.185.6.1113","volume":"185","author":"EF Rosloniec","year":"1997","unstructured":"Rosloniec EF, Brand DD, Myers LK, Whittington KB, Gumanovskaya M, Zaller DM, Woods A, Altmann DM, Stuart JM, Kang AH: An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen. J Exp Med. 1997, 185: 1113-1122. 10.1084\/jem.185.6.1113.","journal-title":"J Exp Med"},{"key":"4100_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/0022-1759(95)00002-R","volume":"180","author":"V Kouskoff","year":"1995","unstructured":"Kouskoff V, Signorelli K, Benoist C, Mathis D: Cassette vectors directing expression of T cell receptor genes in transgenic mice. J Immunol Methods. 1995, 180: 273-280. 10.1016\/0022-1759(95)00002-R.","journal-title":"J Immunol Methods"},{"key":"4100_CR6","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1002\/art.20289","volume":"50","author":"X He","year":"2004","unstructured":"He X, Rosloniec EF, Myers LK, McColgan WL, Gumanovskaya M, Kang AH, Stuart JM: T cell receptors recognizing type II collagen in HLA-DR-transgenic mice characterized by highly restricted V beta usage. Arthritis Rheum. 2004, 50: 1996-2004. 10.1002\/art.20289.","journal-title":"Arthritis Rheum"},{"key":"4100_CR7","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.4049\/jimmunol.174.7.3978","volume":"174","author":"KA Latham","year":"2005","unstructured":"Latham KA, Whittington KB, Zhou R, Qian Z, Rosloniec EF: Ex vivo characterization of the autoimmune T cell response in the HLA-DR1 mouse model of collagen-induced arthritis reveals long-term activation of type II collagen-specific cells and their presence in arthritic joints. J Immunol. 2005, 174: 3978-3985.","journal-title":"J Immunol"},{"key":"4100_CR8","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.4049\/jimmunol.177.6.3884","volume":"177","author":"EF Rosloniec","year":"2006","unstructured":"Rosloniec EF, Ivey RA, Whittington KB, Kang AH, Park HW: Crystallographic structure of a rheumatoid arthritis MHC susceptibility allele, HLA-DR1 (DRB1*0101), complexed with the immunodominant determinant of human type II collagen. J Immunol. 2006, 177: 3884-3892.","journal-title":"J Immunol"},{"key":"4100_CR9","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1002\/art.30454","volume":"63","author":"LK Myers","year":"2011","unstructured":"Myers LK, Cullins DL, Brand DD, Kleinau S, Stuart JM, Kang AH: T cells stimulated with an analog peptide of type II collagen require the Fc receptor gamma-chain to secrete interleukin-4 and suppress autoimmune arthritis in mice. Arthritis Rheum. 2011, 63: 2661-2670. 10.1002\/art.30454.","journal-title":"Arthritis Rheum"},{"key":"4100_CR10","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1093\/rheumatology\/kes035","volume":"51","author":"TL Vincent","year":"2012","unstructured":"Vincent TL, Williams RO, Maciewicz R, Silman A, Garside P: Mapping pathogenesis of arthritis through small animal models. Rheumatology (Oxford). 2012, 51: 1931-1941. 10.1093\/rheumatology\/kes035.","journal-title":"Rheumatology (Oxford)"},{"key":"4100_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00281-003-0127-1","volume":"25","author":"DD Brand","year":"2003","unstructured":"Brand DD, Kang AH, Rosloniec EF: Immunopathogenesis of collagen arthritis. Springer Semin Immunopathol. 2003, 25: 3-18. 10.1007\/s00281-003-0127-1.","journal-title":"Springer Semin Immunopathol"},{"key":"4100_CR12","doi-asserted-by":"publisher","first-page":"v3","DOI":"10.1093\/rheumatology\/kes113","volume":"51","author":"E Choy","year":"2012","unstructured":"Choy E: Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012, 51: v3-v11. 10.1093\/rheumatology\/kes113.","journal-title":"Rheumatology (Oxford)"},{"key":"4100_CR13","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1093\/rheumatology\/ker224","volume":"50","author":"C Salliot","year":"2011","unstructured":"Salliot C, Dawidowicz K, Lukas C, Guedj M, Paccard C, Benessiano J, Dougados M, Nicaise P, Meyer O, Dieude P: PTPN22 R620W genotype-phenotype correlation analysis and gene-environment interaction study in early rheumatoid arthritis: results from the ESPOIR cohort. Rheumatology (Oxford). 2011, 50: 1802-1808. 10.1093\/rheumatology\/ker224.","journal-title":"Rheumatology (Oxford)"},{"key":"4100_CR14","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.3899\/jrheum.120040","volume":"39","author":"WC Chang","year":"2012","unstructured":"Chang WC, Woon PY, Wei JC, Chang CM, Hsu YW, Guo YC, Hwang DY, Kochi Y, Yen JH: A Single-nucleotide Polymorphism of CCR6 (rs3093024) is associated with susceptibility to rheumatoid arthritis but not ankylosing spondylitis, in a Taiwanese population. J Rheumatol. 2012, 39: 1765-10.3899\/jrheum.120040.","journal-title":"J Rheumatol"},{"key":"4100_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3899\/jrheum.120257","volume":"89","author":"F Iannone","year":"2012","unstructured":"Iannone F, Lapadula G: The inhibitor of costimulation of T cells: abatacept. J Rheumatol Suppl. 2012, 89: 100-102. 10.3899\/jrheum.120257.","journal-title":"J Rheumatol Suppl"},{"key":"4100_CR16","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3892\/ijmm.2012.1152","volume":"30","author":"Y Kitagishi","year":"2012","unstructured":"Kitagishi Y, Kobayashi M, Yamashina Y, Matsuda S: Elucidating the regulation of T cell subsets (Review). Int J Mol Med. 2012, 30: 1255-1260.","journal-title":"Int J Mol Med"},{"key":"4100_CR17","first-page":"1193","volume":"147","author":"WW Hancock","year":"1995","unstructured":"Hancock WW, Polanski M, Zhang J, Blogg N, Weiner HL: Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E. Am J Pathol. 1995, 147: 1193-1199.","journal-title":"Am J Pathol"},{"key":"4100_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/00000441-200404000-00007","volume":"327","author":"LK Myers","year":"2004","unstructured":"Myers LK, Sakurai Y, Rosloniec EF, Stuart JM, Kang AH: An analog peptide that suppresses collagen-induced arthritis. Am J Med Sci. 2004, 327: 212-216. 10.1097\/00000441-200404000-00007.","journal-title":"Am J Med Sci"},{"key":"4100_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.autrev.2009.02.024","volume":"9","author":"JP Peron","year":"2009","unstructured":"Peron JP, de Oliveira AP, Rizzo LV: It takes guts for tolerance: the phenomenon of oral tolerance and the regulation of autoimmune response. Autoimmun Rev. 2009, 9: 1-4. 10.1016\/j.autrev.2009.02.024.","journal-title":"Autoimmun Rev"},{"key":"4100_CR20","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.4049\/jimmunol.162.5.2613","volume":"162","author":"LV Rizzo","year":"1999","unstructured":"Rizzo LV, Morawetz RA, Miller-Rivero NE, Choi R, Wiggert B, Chan CC, Morse HC, Nussenblatt RB, Caspi RR: IL-4 and IL-10 are both required for the induction of oral tolerance. J Immunol. 1999, 162: 2613-2622.","journal-title":"J Immunol"},{"key":"4100_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cyto.2012.09.009","volume":"61","author":"H Zhu","year":"2012","unstructured":"Zhu H, Lei X, Liu Q, Wang Y: Interleukin-10\u20131082A\/G polymorphism and inflammatory bowel disease susceptibility: a meta-analysis based on 17,585 subjects. Cytokine. 2012, 61: 146-153.","journal-title":"Cytokine"},{"key":"4100_CR22","doi-asserted-by":"publisher","first-page":"e47435","DOI":"10.1371\/journal.pone.0047435","volume":"7","author":"Y Gong","year":"2012","unstructured":"Gong Y, Wang Z, Liang Z, Duan H, Ouyang L, Yu Q, Xu Z, Shen G, Weng X, Wu X: Soluble MOG35-55\/I-A(b) Dimers Ameliorate Experimental Autoimmune Encephalomyelitis by Reducing Encephalitogenic T Cells. PLoS One. 2012, 7: e47435-10.1371\/journal.pone.0047435.","journal-title":"PLoS One"},{"key":"4100_CR23","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, CONFIRM study investigators: Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012, 367: 1087-1097. 10.1056\/NEJMoa1206328.","journal-title":"N Engl J Med"},{"key":"4100_CR24","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","volume":"45","author":"KP Johnson","year":"1995","unstructured":"Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995, 45: 1268-1276. 10.1212\/WNL.45.7.1268.","journal-title":"Neurology"},{"key":"4100_CR25","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1212\/WNL.50.3.701","volume":"50","author":"KP Johnson","year":"1998","unstructured":"Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Volmer T, Weiner LP, Wolinsky JS: Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998, 50: 701-708. 10.1212\/WNL.50.3.701.","journal-title":"Neurology"},{"key":"4100_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ana.22316","volume":"69","author":"G Comi","year":"2011","unstructured":"Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M, Group FS: Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol. 2011, 69: 75-82. 10.1002\/ana.22316.","journal-title":"Ann Neurol"},{"key":"4100_CR27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ana.23863","volume":"73","author":"FD Lublin","year":"2013","unstructured":"Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, Salter AR, Gustafson T, Wolinsky JS, CombiRx I: Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013, 73: 327-340. 10.1002\/ana.23863.","journal-title":"Ann Neurol"},{"key":"4100_CR28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/1471-2377-12-124","volume":"12","author":"M Giannini","year":"2012","unstructured":"Giannini M, Portaccio E, Ghezzi A, Hakiki B, Pasto L, Razzolini L, Piscolla E, De Giglio L, Pozzilli C, Paolicelli D, Trojano M, Marrosu MG, Patti F, La Mantia L, Mancardi G, Solaro C, Totaro R, Tolar MR, De Luca G, Lugaresi A, Moiola L, Martinelli V, Comi G, Amato MP: Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol. 2012, 12: 124-10.1186\/1471-2377-12-124.","journal-title":"BMC Neurol"},{"key":"4100_CR29","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1002\/art.1780380811","volume":"38","author":"S Yoshino","year":"1995","unstructured":"Yoshino S, Quattrocchi E, Weiner HL: Suppression of antigen-induced arthritis in Lewis rats by oral administration of type II collagen. Arthritis Rheum. 1995, 38: 1092-1096. 10.1002\/art.1780380811.","journal-title":"Arthritis Rheum"},{"key":"4100_CR30","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s001090100259","volume":"79","author":"B Bielekova","year":"2001","unstructured":"Bielekova B, Martin R: Antigen-specific immunomodulation via altered peptide ligands. J Mol Med. 2001, 79: 552-565. 10.1007\/s001090100259.","journal-title":"J Mol Med"},{"key":"4100_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4110\/in.2012.12.4.139","volume":"12","author":"D Choi","year":"2012","unstructured":"Choi D, Kim TG, Sung YC: The past, present, and future of adoptive T cell therapy. Immune Netw. 2012, 12: 139-147. 10.4110\/in.2012.12.4.139.","journal-title":"Immune Netw"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4433.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar4433\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4433.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:09:22Z","timestamp":1728382162000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar4433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,10]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,2]]}},"alternative-id":["4100"],"URL":"https:\/\/doi.org\/10.1186\/ar4433","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,10]]},"assertion":[{"value":"1 April 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R7"}}